E. Collins

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.

S. A. Watkins, M. Vieth, R. Campbell, 2004, Molecular cancer therapeutics.

Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.

S. A. Watkins, M. Vieth, R. Campbell, 2004, Bioorganic & medicinal chemistry letters.

Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.

S. A. Watkins, D. Robertson, C. Hamdouchi, 2005, Bioorganic & medicinal chemistry letters.

Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.

E. Collins, M. Bowyer, A. McCluskey, 2000, Bioorganic & medicinal chemistry letters.

Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase

Hui Yang, Jack Dempsey, Xiang Ye, 2005, FEBS letters.

Identification of potent and selective MMP-13 inhibitors.

T. Rush, E. Collins, J. Levin, 2005, Bioorganic & medicinal chemistry letters.

Identification of potent and selective MMP-13 inhibitors.

T. Rush, E. Collins, J. Levin, 2005, Bioorganic & medicinal chemistry letters.